231 related articles for article (PubMed ID: 29635526)
1. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater.
Makino K; Nakagawa T; Ito E; Kasahara I; Murata T; Fujimura T; Fukuhara H; Homma Y
Jpn J Clin Oncol; 2018 May; 48(5):485-490. PubMed ID: 29635526
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
3. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
Hajili T; Ohlmann CH; Linxweiler J; Niklas C; Janssen M; Siemer S; Stoeckle M; Saar M
BJU Int; 2019 Jan; 123(1):58-64. PubMed ID: 29772100
[TBL] [Abstract][Full Text] [Related]
6. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
8. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
Si S; Zheng B; Wang Z; Niu Z
Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739
[TBL] [Abstract][Full Text] [Related]
9. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
10. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
Abbas F; Kaplan M; Soloway MS
Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
[TBL] [Abstract][Full Text] [Related]
11. Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy.
Milonas D; Laenen A; Venclovas Z; Jarusevicius L; Devos G; Joniau S
Clin Transl Oncol; 2022 Feb; 24(2):371-378. PubMed ID: 34453699
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
13. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
14. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
[TBL] [Abstract][Full Text] [Related]
15. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
16. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
Heidenreich A; Pfister D; Brehmer B; Porres D
Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
[TBL] [Abstract][Full Text] [Related]
17. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
18. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
19. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Qi N; Mao L
Cancer Med; 2023 Feb; 12(4):4352-4356. PubMed ID: 36106643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]